Request FREE sample PDF
Pharmacy benefit management market
transdermal patch market Report Overview
The global transdermal patch market size was estimated at USD 7058.3 million in 2022 and will reach USD 9712.17 million by 2031, at CAGR of 3.6% during the forecast period.
The COVID-19 pandemic has been unprecedented and staggering, with the transdermal patch market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels.
Transdermal patches are innovative medical devices designed to deliver medications through the skin and into the bloodstream. They offer a convenient and non-invasive method of drug administration, making them highly advantageous for patients. These patches are used in various therapeutic applications, including pain management, hormone replacement therapy, and nicotine replacement therapy.
The increasing awareness among patients and healthcare professionals regarding the benefits of these patches is a key driver for transdermal patch market growth. Healthcare providers appreciate the ease of use of these patches, which contribute to patient compliance. Furthermore, the ability of these patches to maintain controlled levels of medication over an extended period adds to their appeal. As patients and healthcare providers continue to recognize the advantages of transdermal drug delivery, the market is expected to witness substantial growth. This growing acceptance and understanding of the benefits of these patches contributes to the market's upward trajectory, along with the rising demand for effective chronic disease management solutions.
COVID-19 Impact: Demand Declined Due to Cancellation of Elective Medical Procedures
The COVID-19 pandemic significantly impacted this market. One of the key effects was the reduced demand as patients postponed or canceled elective medical procedures and visits to the doctor. With a decrease in routine medical consultations, there was a corresponding decline in the number of new prescriptions for transdermal patches. Patients were often hesitant to seek non-essential medical care, which had a direct impact on the overall demand for these patches.
During the pandemic, there was a heightened focus on essential medications, particularly those used in the treatment of COVID-19 and other severe illnesses. This shift in medical priorities influenced healthcare professionals' prescription practices, with a tendency to prioritize essential medications over non-essential options like these patches. As a result, some patients who might have otherwise been prescribed these patches found it less likely to receive such prescriptions during the pandemic. The increased emphasis on critical treatments played a role in the reduced demand for these patches in the healthcare landscape.
The pandemic-induced changes in patient behavior and healthcare practices had a noticeable impact on this market. While these patches offer valuable benefits, the disruption caused by the pandemic, including reduced patient visits and an increased focus on essential medications, led to a decline in demand across various regions. However, as healthcare services have gradually returned to normal, the market is expected to rebound as patients regain trust in seeking non-invasive and effective drug delivery solutions like these patches.
Latest Trends
"Development of Rivastigmine and Docetaxel Patches to Address Broader Range of Medical Conditions"
A significant and promising trend in the market is the development of new patches designed to address a broader range of medical conditions. These innovative transdermal patches offer a convenient way to deliver medications, making them an attractive choice for patients and healthcare providers alike. Some notable examples of these patches include the rivastigmine patch for Alzheimer's disease, the docetaxel patch for cancer treatment, and the insulin patch for diabetes management.
The rivastigmine patch, specifically designed for Alzheimer's disease, is applied to the skin once a day, providing a continuous release of the drug over a 24-hour period. This method simplifies medication management for Alzheimer's patients and offers a potentially more effective approach to treatment. In the realm of cancer therapy, the docetaxel patch has been developed to deliver chemotherapy to patients with various forms of cancer, including breast cancer, lung cancer, and prostate cancer. Administered once a week, this patch ensures a consistent release of docetaxel over a 7-day period, offering potential advantages in terms of treatment adherence and effectiveness.
For individuals with diabetes, the insulin patch represents an exciting development. This patch administers insulin, a crucial medication for diabetes management, on a daily basis, maintaining stable insulin levels over a 24-hour period. As these new patches continue to emerge, they are poised to play an increasingly vital role in the treatment of chronic diseases and a diverse range of medical conditions, promising improved patient outcomes and enhanced convenience in drug delivery.
transdermal patch market Segmentation
- By Type Analysis
According to type, the market can be segmented into methyl salicylate-based patches, rivastigmine patches, fentanyl patches, lidocaine patches, diclofenac patches, nicotine patches, and others.
- By Application Analysis
Based on application, the market can be divided into the Rx channel and the OTC channel.
Driving Factors
"Increasing Prevalence of Chronic Diseases to Act as Catalyst Behind Market Expansion"
One of the primary driving forces behind the expansion of this market is the growing prevalence of chronic diseases. Conditions such as chronic pain, diabetes, and cardiovascular diseases are becoming increasingly common. Transdermal patches offer a convenient and highly effective method for delivering medications to patients suffering from these ailments. As the number of individuals afflicted by chronic conditions continues to rise, the demand for this treatment technology is expected to surge in the coming years. This trend is indicative of the crucial role that these patches play in enhancing the quality of life for those with chronic health issues.
"Rising Awareness of Product to Propel Market Growth"
Another significant factor propelling the demand for the product is the increasing awareness among both patients and healthcare professionals about the advantages it offers. Transdermal patches are valued for their ease of use and ability to provide consistent and controlled levels of medication over an extended period. This heightened awareness of the benefits associated with these patches is anticipated to drive their adoption in various therapeutic areas. As more individuals and healthcare providers recognize the advantages of this drug delivery method, this market is poised for substantial growth in the near future.
Restraining Factors
"Skin Sensitivity and Allergic Reactions to Limit Product Utilization"
Several individuals may experience skin sensitivity or develop allergic reactions in response to the adhesive components commonly found in transdermal patches. This not only restricts the broad applicability of these patches but also underscores the need for extensive research and the development of hypo-allergenic alternatives to ensure a wider range of patients can benefit from this drug delivery method.
transdermal patch market Regional Insights
"North America Leads Due to the Region’s Robust Healthcare Infrastructure"
North America holds the largest transdermal patch market share due to a robust healthcare infrastructure, the presence of major industry players, and a substantial focus on research and development activities. With a strong foundation of healthcare facilities, North America offers a significant market for these patches, while the presence of industry leaders in the region enhances its competitive edge. Moreover, the region's commitment to research and development leads to continuous advancements in this patch technology, addressing a broader range of medical conditions and solidifying North America's prominent position in the global market.
Key Industry Players
"Key Players Focus on Partnerships to Gain a Competitive Advantage"
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.
List of Market Players Profiled
- Hisamitsu Pharmaceutical (Japan)
- Johnson & Johnson (U.S.)
- Novartis (Switzerland)
- UCB Pharma (Belgium)
- Mylan (U.S.)
- Teva Pharmaceutical (Israel)
- Nitto Denko (Japan)
- Grünenthal (Germany)
- IBSA Group (Switzerland)
- GSK (GlaxoSmithKline, U.K.)
- Luye Pharma Group (China)
- Pfizer (U.S.)
- Chattem (U.S.)
- Dr. Reddy’s Laboratories (India)
- Bayer (Germany)
- Mundipharma (U.K.)
- Endo International (Ireland)
- Beijing Tide Pharmaceutical (China)
Report Coverage
This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 7058.3 Million in 2022 |
Market Size Value By |
US$ 9712.17 Million by 2031 |
Growth Rate |
CAGR of 3.6% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the global transdermal patch market expected to reach by 2031?
The global transdermal patch market is expected to reach a readjusted size of USD 9712.17 million by 2031.
-
What CAGR is the transdermal patch market expected to exhibit by 2031?
The transdermal patch market is expected to exhibit a CAGR of 3.6% by 2031.
-
What are the driving factors of the transdermal patch market?
The driving factors of transdermal patch market include the increasing prevalence of chronic diseases and the rising awareness of the benefits of these patches.
-
Which are the key players or most dominant companies functioning in the transdermal patch market?
The dominant companies in the transdermal patch market are Hisamitsu Pharmaceutical, Johnson & Johnson, Novartis, UCB Pharma, Mylan, Teva Pharmaceutical, Nitto Denko, Grünenthal, IBSA Group, GSK, Luye Pharma Group, Pfizer, Chattem, and Dr Reddy’s Laboratories.